Alecensa 150mg
Introduction to the drug alectinib or alensa in the treatment of metastatic lung cancer
Alectinib is an oral chemotherapy drug used for non-small cell lung cancer, metastatic lung cancer, and is manufactured by Hoffmann-La Roche in Japan. Its trade name is Alecensa and it is part of the group of targeted cancer drugs, Target therapy. Its generic version has not yet been developed and is available to patients as a brand name under the name Alecensa.
Alectinib, a drug for the treatment of malignant lung cancer
Alectinib was approved by the FDA in December 2015 and by the European Medicines Agency in February 2017.
Alcensa is a tyrosine kinase inhibitor and is used to treat patients with non-small cell lung cancer that has spread to the rest of the body and is ALK-positive, in which case the cancer cells may metastasize to the bones, heart wall, abdomen , and liver.
ALK is a gene that, when disrupted, causes non-small cell lung cancer, or metastatic lung cancer.
نمونه محصولات شرکت
